PROTAC as a novel anti-cancer strategy by targeting aging-related signaling

被引：0
|
作者：
Peng, Yunhua [1 ,2 ]
Liu, Donghua [1 ,3 ,4 ]
Huang, Daoyuan [5 ]
Inuzuka, Hiroyuki [5 ]
Liu, Jing [1 ,3 ,4 ]
机构：
[1] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, Xian 710061, Peoples R China
[2] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Ctr Mitochondrial Biol & Med,Key Lab Biomed Inform, Xian 710049, Peoples R China
[3] Xi An Jiao Tong Univ, Key Lab Tumor Precis Med Shaanxi Prov, Affiliated Hosp 1, Xian 710061, Peoples R China
[4] Minist Educ, Key Lab Environm & Genes Related Dis, Xian 710061, Peoples R China
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
来源：
SEMINARS IN CANCER BIOLOGY | 2024年 / 106卷
基金：
中国国家自然科学基金;
关键词：
PROteolysis-TArgeting Chimera (PROTAC); Cancer therapy; Protein degradation; Senescence; CELL-CYCLE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TELOMERASE; SENESCENCE; CANCER; INHIBITORS; P53; HALLMARKS; OLAPARIB;
D O I：
10.1016/j.semcancer.2024.09.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aging and cancer share common cellular hallmarks, including cellular senescence, genomic instability, and abnormal cell death and proliferation, highlighting potential areas for therapeutic interventions. Recent advancements in targeted protein degradation technologies, notably Proteolysis-Targeting Chimeras (PROTACs), offer a promising approach to address these shared pathways. PROTACs leverage the ubiquitin-proteasome system to specifically degrade pathogenic proteins involved in cancer and aging, thus offering potential solutions to key oncogenic drivers and aging-related cellular dysfunction. This abstract summarizes the recent progress of PROTACs in targeting critical proteins implicated in both cancer progression and aging, and explores future perspectives in integrating these technologies for more effective cancer treatments.
引用
收藏
页码：143 / 155
页数：13
相关论文
共 50 条
  • [1] Targeting mTOR for Anti-Aging and Anti-Cancer Therapy
    Fu, Wencheng
    Wu, Geng
    MOLECULES, 2023, 28 (07):
  • [2] Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy
    Xu, Wei
    Lukkarila, Julie L.
    da Silva, Sara R.
    Paiva, Stacey-Lynn
    Gunning, Patrick T.
    Schimmer, Aaron D.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (18) : 3201 - 3209
  • [3] Targeting metabolism to influence cellular senescence a promising anti-cancer therapeutic strategy
    Wang, Zehua
    Gao, Jianwen
    Xu, Congjian
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 177
  • [4] Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway
    Shah, Karmani
    Panchal, Shivangi
    Patel, Bhumika
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [5] Anti-Cancer Immunotherapies Targeting Telomerase
    Negrini, Simone
    De Palma, Raffaele
    Filaci, Gilberto
    CANCERS, 2020, 12 (08) : 1 - 23
  • [6] Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins
    Kim, Hyejin
    Jung, Inkyung
    Lee, Chan Hyeong
    An, Jungeun
    Ko, Myunggon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (22)
  • [7] Efficacy of an anti-cancer strategy targeting SET in canine osteosarcoma
    Tsuji, Shunya
    Ohama, Takashi
    Nakagawa, Takayuki
    Sato, Koichi
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2019, 81 (10) : 1424 - 1430
  • [8] Targeting WDR5: A WINning Anti-Cancer Strategy?
    Aho, Erin R.
    Weissmiller, April M.
    Fesik, Stephen W.
    Tansey, William P.
    EPIGENETICS INSIGHTS, 2019, 12
  • [9] Anti-Cancer Targeting Telomerase Inhibitors: β-Rubromycin and Oleic Acid
    Mizushina, Yoshiyuki
    Takeuchi, Toshifumi
    Sugawara, Fumio
    Yoshida, Hiromi
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (11) : 1135 - 1143
  • [10] Small Molecules Targeting Biological Clock; A Novel Prospective for Anti-Cancer Drugs
    Rahman, Sadia
    Wittine, Karlo
    Sedic, Mirela
    Markova-Car, Elitza P.
    MOLECULES, 2020, 25 (21):
12345